Yahoo · Sep 11, 2026
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UT
NYSE · UTHR
United Therapeutics Corporation
Healthcare · Biotechnology
$500.35
Down-$2.35 (-0.47%)
Updated Sep 16, 2026, 6:45 AM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 21.83B
- P/E ratio
- 16.83
- Dividend yield
- 0.00%
- 52-week range
- $396.12 – $609.35
- Volume
- 1.6M
- Avg. volume
- 627.5K
Price performance
UTHR price history
1M range · 20 trading sessions · Daily adjusted prices
UTHR closed at $500.35 after 20 trading sessions, down 3.46% for the selected period.
- Last close
- $500.35
- Period change
- -3.46%
- Period low
- $487.61
- Period high
- $529.14
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $505.44 | $507.15 | $498.85 | $500.35 | 1.6M |
| Sep 14, 2026 | $506.78 | $509.065 | $499.62 | $502.70 | 605.73K |
| Sep 11, 2026 | $505.60 | $508.675 | $496.18 | $497.11 | 573.36K |
| Sep 10, 2026 | $502.44 | $509.79 | $497.91 | $503.86 | 653.16K |
| Sep 9, 2026 | $502.75 | $509.525 | $492.90 | $506.82 | 500.11K |
| Sep 8, 2026 | $494.74 | $505.00 | $479.71 | $497.97 | 643.54K |
| Sep 4, 2026 | $484.33 | $494.085 | $484.33 | $487.61 | 327.02K |
| Sep 3, 2026 | $494.09 | $494.09 | $477.06 | $490.24 | 469.58K |
| Sep 2, 2026 | $510.00 | $510.05 | $477.01 | $492.02 | 1.4M |
| Sep 1, 2026 | $514.20 | $517.75 | $510.39 | $512.70 | 479K |
| Aug 31, 2026 | $510.95 | $515.55 | $507.03 | $510.38 | 538.52K |
| Aug 28, 2026 | $527.94 | $530.50 | $513.72 | $515.46 | 266.87K |
| Aug 27, 2026 | $513.98 | $531.76 | $511.00 | $527.91 | 391.01K |
| Aug 26, 2026 | $515.60 | $522.0199 | $513.98 | $516.68 | 254.78K |
| Aug 25, 2026 | $516.07 | $520.655 | $515.54 | $518.53 | 876.5K |
| Aug 24, 2026 | $513.12 | $514.295 | $508.1541 | $512.88 | 323.89K |
| Aug 21, 2026 | $523.23 | $528.02 | $512.29 | $513.12 | 415.57K |
| Aug 20, 2026 | $524.15 | $529.255 | $517.88 | $521.00 | 440.39K |
| Aug 19, 2026 | $525.47 | $535.77 | $522.04 | $529.14 | 432.11K |
| Aug 18, 2026 | $510.42 | $519.21 | $508.56 | $518.27 | 366.43K |
Latest UTHR news
The latest Smart Investors Daily articles mentioning UTHR.
Stock researchCompany · Overview
UTHR research
Overview
Company profile and research snapshot.
Company profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $539.83
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jul 23, 2026 | JP Morgan | Overweight | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| May 7, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?
United Therapeutics Corporation (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion authorization to an accelerated share repurchase with Citibank, N.A. on September 8. Earlier transactions included $1.5 billion of accelerated repurchases and $22.4 million of open-market purchases. The upfront payment was scheduled for around September 10, with initial delivery representing approximately 75% of […]
Yahoo · Sep 9, 2026
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers.
SeekingAlpha · Sep 9, 2026
United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
United Therapeutics Corporation (UTHR) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 2:10 PM EDTCompany ParticipantsMartine...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
